Myrava acquires Ricoh 3D for Healthcare, Ricoh USA’s patient-specific medical AM unit

Myrava has acquired Ricoh 3D for Healthcare, Ricoh USA’s unit that manufactures patient-specific medical devices via additive manufacturing. Ricoh had carved the operation into a standalone business only in 2025 after running it as an internal medical AM center. Gary Turner, previously vice president and general manager of that unit, now leads Myrava as chief executive and frames the purchase as the path to independent growth focused on FDA-approved personalized devices and point-of-care manufacturing. Purchase price, headcount, sites, and product-line detail were not disclosed.

The deal is a corporate carve-out of specialized medical AM production that no longer fits a diversified industrial-services agenda. Ricoh is concentrating on process automation, workplace design, and business-process services; Bob Lamendola, Ricoh USA’s chief digital services and delivery officer, said patient-specific devices demand skills beyond those broader priorities, even as healthcare remains a growth market for the parent. For Myrava, the prize is a going concern rather than a machine brand: FDA-facing personalized-device workflows, point-of-care manufacturing practice, and U.S. clinical relationships already embedded in delivery pathways. Leadership continuity under Turner lowers the usual post-deal risk that quality systems, hospital contracts, and process controls fracture when a conglomerate exits the line of business.

What Myrava must prove is medical AM service economics without the parent’s balance sheet: sustain FDA-approved personalized production, fund the quality organization, and convert point-of-care manufacturing from pilot language into reliable hospital throughput. If regulatory continuity and customer contracts travel intact, Myrava gains a focused U.S. platform in patient-specific devices; if those assets are thinly documented or undercapitalized, independence becomes a cost center rather than a growth engine.